Phase II study to assess efficacy and safety of metronomic oral Idarubicin in patients with hepatocarcinoma at intermediate-advanced stage after failure or intolerance to Sorafenib and Regorafenib
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Idarubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms Metro IDA
- 10 Mar 2022 Status changed from recruiting to discontinued.
- 06 Oct 2021 New trial record